ReviewDer Nervenarzt2026
[Neuromodulation as the fourth pillar in the treatment of depression : A position paper of the German Center for Mental Health].
Review in Der Nervenarzt, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDepressive disorders are associated with a high burden of disease; a substantial proportion of patients show insufficient response despite guideline-based pharmacotherapy and psychotherapy, particularly in treatment-resistant depression (TRD). Neuromodulation has become established as a fourth pillar in the treatment of depression and includes electroconvulsive therapy (ECT), repetitive transcranial magnetic stimulation (rTMS), vagus nerve stimulation (VNS), transcranial electrical stimulation (tES), magnetic seizure therapy (MST), deep brain stimulation (DBS) and neurofeedback (NF). Despite partly well-established efficacy, these interventions remain insufficiently integrated into routine clinical care. The aim of this paper is to summarize the current evidence and to analyze key barriers to implementation. MATERIAL AND
methodsNarrative review of clinical studies, meta-analyses, and care data on efficacy, safety and cognitive tolerability.
resultsThe strongest evidence for both acute and maintenance treatment of severe depressive disorders is for ECT; rTMS is effective and cognitively well tolerated and VNS can represent an additive long-term option in TRD. For tES, small and heterogeneous effects have been reported, MST and DBS remain experimental and for NF consistent evidence of efficacy is lacking. Key barriers include partly heterogeneous protocols, insufficient funding structures, particularly in the outpatient setting and the absence of standardized qualification requirements.
conclusionNeuromodulation should be systematically integrated into staged-care models. Standardized protocols and registry-based research are needed to enable the structured and sustainable implementation of neuromodulatory interventions in clinical care.
Indexed as
Identifiers
42554808What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.